Adjuvant Pembrolizumab for Resected NSCLC

home / approval-alert / adjuvant-pembrolizumab-for-resected-nsclc

Adjuvant Pembrolizumab for Resected NSCLC

Articles
The FDA approved adjuvant pembrolizumab for the treatment of patients with resected non–small cell lung cancer, based on data from the phase 3 KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15-PEARLS trial.

FDA OKs Adjuvant Pembrolizumab for Resected NSCLC

January 26th 2023

The FDA approved adjuvant pembrolizumab for the treatment of patients with resected non–small cell lung cancer, based on data from the phase 3 KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15-PEARLS trial.

Videos
An expert from Yale School of Medicine discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression.

Adjuvant Pembrolizumab Approval Adds to Prevention of Recurrent NSCLC

February 2nd 2023

An expert from Yale School of Medicine discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression.